Tenofovir Disoproxil Fumarate vs Placebo in Pediatric Chronic Hepatitis B

Phase 3, randomised, double-blind trial in hepatitis B (HBV) comparing Viread with Placebo (2 arms). Primary endpoints: Percentage of participants with serum HBV DNA < 400 copies/mL (69 IU/mL) at Week 48 (missing = failure approach) and Percentage of participants with serum HBV DNA < 400 copies/mL (69 IU/mL) at Week 48 (missing = excluded approach). Started Nov 2024; status: completed.